Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Sell rating on Sarepta Therapeutics (SRPT – Research Report). The associated ...
In year two of the trial, Elevidys demonstrated statistically significant and clinically improvements across three key ...
The gene therapy improved motor functions in children with Duchenne muscular dystrophy two years after treatment ...
Shares of Sarepta (SRPT) are down this morning, potentially due to the latest FDA Adverse Event Reporting System update on Elevidys, which ...
RBC Capital analyst Brian Abrahams says shares of Sarepta (SRPT) could be trading lower today on an FDA database update that ...
Swiss pharma giant Roche today announced positive top-line results from year two of the EMBARK trial, a global, randomized, ...
GlobalData on MSN2d
Roche reports positive topline outcomes from DMD treatment trialRoche has reported positive topline outcomes from the second year of the multinational Phase III EMBARK trial of Elevidys ...
Roche announces positive results from EMBARK phase III study of Elevidys in ambulatory individuals with DMD: Basel Tuesday, January 28, 2025, 11:00 Hrs [IST] Roche announced posit ...
Roche and Sarepta Therapeutics have shared positive top-line results from a late-stage study of Elevidys (delandistrogene ...
Sarepta Therapeutics' Elevidys for DMD shows revenue potential, with market cap justified at $11.4bn and potential for >50% ...
It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%.” - The Business Research Company LONDON, GREATER LONDON, UNITED KINGDOM, January ...
Roche on Monday revealed positive results from the EMBARK trial, showing that its gene therapy Elevidys has sustained benefits for individuals with Duchenne muscular dystrophy (DMD) over a two-year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback